The APS Science Policy Committee’s symposium at Experimental Biology 2015 explored scientific rigor and the issues that affect the reliability of research results.
-
Carrie Northcott, Pfizer
Symposium Chair and Moderator, APS Science Policy Committee
-
Shai Silberberg, NINDS/NIH
How do we improve research methods and reporting?
-
Malcolm Macleod, Edinburgh University
Animal models for human diseases—how can we improve translation of effects to humans?
-
Richard Nakamura, CSR
What role should peer review play assessing study design and evaluating the “scientific premise” of proposals?
Abstract
A lack of consistent reproducibility in some pre-clinical research has serious implications for translating those findings from bench to bedside. This is a problem that requires urgent corrective action. Restoring confidence in the rigor of pre-clinical biomedical research will require all stakeholders to be a part of the solution, including basic scientists, academic institutions, industry, and publishers. NIH is committed to increasing the rigor and reliability of pre-clinical research, but funding agencies alone cannot address all the elements of the problem. Restoring confidence in pre-clinical biomedical research will require all stake-holders to be a part of the solution, including basic scientists, academic institutions, industry, and publishers. Improving reproducibility will require us to be involved, proactive, and willing to think and act differently.
Stay Connected
Get Advocacy Alerts and the latest news by connecting with the Society’s Science Policy Team around the web